Replies to post #102843 on Biotech Values

[DewDiligence]

Is [SNY’s] immediate 4% reduction projection (earnings or revenue, I can't recall?) factoring an enoxaparin price war into it?

By simple arithmetic, the answer is clearly not. The 4% guidance reduction was for 2010 EPS (http://en.sanofi-aventis.com/binaries/20100723_enoxaparine_en_tcm28-28977.pdf ).

[10nisman]

Healthtrust, and other GPOs, had pricing of WAC - 30% prior to M-enox approval. On the day of approval SNY came down another 1000 basis points to WAC - 40% to Healthtrust members, and as it turns out, most GPOs.

So your saying SNY lowered its pricing an additional 10% (or 14% on a revenue basis) compared to its GPO pricing prior to Sandoz/MNTA approval? I don't see that as an attempt or a willingness to start a price war.

10nis